Clinical trials
Phase 1 Disease Progression trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
24 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2005 | 2 |
| 2011 | 1 |
| 2012 | 2 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 1 |
| 2025 | 2 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Recruiting | 5 |
| Active, not recruiting | 3 |
| Terminated | 3 |
| Not yet recruiting | 1 |
| Unknown status | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AstraZeneca | 2 |
| National Cancer Institute (NCI) | 2 |
| University of Pennsylvania | 2 |
| Biomea Fusion Inc. | 1 |
| Celgene | 1 |
| Centre hospitalier de l'Université de Montréal (CHUM) | 1 |
| Engeneic Pty Limited | 1 |
| Georgia State University | 1 |
| Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 1 |
| James Liao | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Disease Progression | 24 |
| Neoplasms | 6 |
| Lung Neoplasms | 4 |
| Multiple Myeloma | 4 |
| Brain Neoplasms | 3 |
| Glioblastoma | 3 |
| Recurrence | 3 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Glioma | 2 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 |
Trials
Showing 76 to 24 of 24. Each trial links to its page on Pharma Observatory.
No trials match these filters.
Try a different keyword, or clear a filter.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.